sodium aurotiosulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4707 10210-36-3

Description:

MoleculeDescription

Synonyms:

  • sodium aurotiosulfate
  • thiochrysine
  • aurothiosulfate
  • Molecular weight: 490.17
  • Formula: AuNa3O6S4
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
14 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Taste disorder 108.96 36.00 62 6167 61484 90560734
Infusion site reaction 105.13 36.00 42 6187 18997 90603221
Onychomadesis 94.17 36.00 51 6178 45947 90576271
Product quality issue 73.17 36.00 53 6176 79272 90542946
Nail disorder 72.31 36.00 47 6182 59020 90563198
Back injury 66.83 36.00 41 6188 46581 90575637
Peripheral venous disease 61.75 36.00 49 6180 83872 90538346
Liver function test increased 59.15 36.00 48 6181 84807 90537411
Blepharospasm 53.30 36.00 38 6191 55407 90566811
Lip dry 51.91 36.00 48 6181 100907 90521311
Neck pain 48.81 36.00 49 6180 113914 90508304
Live birth 43.37 36.00 39 6190 79068 90543150
Therapeutic product effect incomplete 42.27 36.00 59 6170 193837 90428381
Breast cancer stage III 41.19 36.00 39 6190 84408 90537810
Hypercholesterolaemia 40.68 36.00 42 6187 100850 90521368
Epilepsy 40.16 36.00 38 6191 82168 90540050
Normal newborn 37.22 36.00 22 6207 23340 90598878
Lung disorder 36.28 36.00 48 6181 149835 90472383

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Taste disorder 119.74 50.01 63 6178 65324 110517734
Infusion site reaction 116.21 50.01 42 6199 17640 110565418
Onychomadesis 104.01 50.01 51 6190 45612 110537446
Product quality issue 86.42 50.01 54 6187 77245 110505813
Nail disorder 81.70 50.01 47 6194 57888 110525170
Back injury 73.71 50.01 41 6200 47358 110535700
Peripheral venous disease 70.29 50.01 49 6192 84068 110498990
Liver function test increased 65.74 50.01 48 6193 88500 110494558
Lip dry 60.51 50.01 48 6193 100035 110483023
Blepharospasm 60.48 50.01 38 6203 54813 110528245
Live birth 54.61 50.01 39 6202 69445 110513613
Neck pain 53.80 50.01 49 6192 123081 110459977
Hypercholesterolaemia 51.57 50.01 42 6199 90795 110492263
Breast cancer stage III 50.09 50.01 39 6202 79078 110503980
Muscle injury 50.05 50.01 50 6191 140757 110442301

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01CB02 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
SPECIFIC ANTIRHEUMATIC AGENTS
Gold preparations

Related Drugs by ATC class:

M01CB Gold preparations 4 drugs
auranofinaurothioglucoseaurotioprolsodium aurothiomalate

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000166205 NUI
33614-49-2 SECONDARY_CAS_RN
CHEBI:755955 CHEBI
CHEMBL3833379 ChEMBL_ID
2235 INN_ID
DB13743 DRUGBANK_ID
CKS1YQ9W1J UNII
9876 RXNORM
006964 NDDF
411326004 SNOMEDCT_US
85494006 SNOMEDCT_US
C0037512 UMLSCUI
161780 PUBCHEM_CID

Pharmaceutical products:

None